TREATING PARKINSON S AND HUNTINGTON S DISEASE WITH CELL THERAPIES- WHY BOTHER?
|
|
- Ferdinand Charles
- 5 years ago
- Views:
Transcription
1 TREATING PARKINSON S AND HUNTINGTON S DISEASE WITH CELL THERAPIES- WHY BOTHER? Roger Barker John van Geest Centre for Brain Repair and Department of Neurology University of Cambridge rab46@cam.ac.uk
2 WHAT IS PARKINSON S DISEASE? MOVEMENT DISORDER Tremor Slowness of movement /Bradykinesia Rigid muscles and NON-MOTOR PROBLEMS And NON-NIGRAL DOPAMINE CELL LOSS
3 TREATING PARKINSON S WITH CELL THERAPIES: WHY BOTHER? PARKINSON S DISEASE REASONS FOR: Common; Incurable; Well defined dopamine nigral cell loss; Responds to dopamine drugs so will respond well to dopamine cell therapies; Drug therapies have long term side effects; Fetal VM trials have shown proof of principle data to support their efficacy REASONS AGAINST: Most people die with rather than from PD; Good dopamine therapies exist for it already; Trials show it does not work with fetal VM tissue; Pathology extends beyond the dopamine system and this causes more significant problems; Grafts acquire PD pathology!
4 Neural grafts HUMAN FETAL VM Replace dopamine cells CURE time spent in "off" (%) time spent in "off" (%) T r a n s p l a n t a t i o n s u r g e r y S e l e g i l i n e 1 0 m g S e l e g i l i n e 1 0 m g P a t i e n t 3 P a t i e n t 4 C y c l o s p o r i n e 0 L - d o p a 0 Key pathology is known i.e. loss of dopaminergic cells in nigra m o n t h s p r e - a n d p o s t - t r a n s p l a n t a t i o n Graft survival and functional improvement EXPERIMENTALLY SHOWN: Allografts of right fetal age survive; Make and receive connections from host; Release DA; Ameliorate most but not all behaviours OPEN LABEL STUDIES in PD PATIENTS: Fetal nigral transplants in PD patients
5 2001 RESULT No significant benefit at 1 year using global rating scale; SIDE-EFFECTS!! Graft induced dyskinesias (GIDs) seen in 15% of patients BUT nevertheless RESULT No significant benefit at 2 year using standard assessment; GIDs seen in 54% of patients
6 Fetal neural cells into rat brain Cell suspensions used But THE OPEN LABEL STUDY FOLLOW UP CONTINUES SO WHAT have we learnt to date about cell based therapies for PD
7 And the data to date Fetal dopamine transplants for PD can be delivered safely- no neurosurgical or tumour concerns. Fetal dopamine transplants can work well for over 10 years in some patients to the extent that they can stop their medication. Fetal dopamine transplants do NOT work in ALL patients with PD. THE NEED FOR A NEW TRIAL?.TRANSEURO AND some patients develop GIDs but only a new where these are bad enough to have DBS and in those cases it works as well as for LIDS..and Pathology can develop in these grafts albeit in low numbers of dopaminergic cells.. Barker et al Lancet Neurology 2013
8 LUND CAMBRIDGE CARDIFF LONDON PARIS FREIBURG VIENNA OPTIMISED THE COLLECTION OF DOPAMINE CELLS FROM THE HUMAN FETAL BRAIN COLLECTED, STUDIED AND OPTIMISED THE ASSESSMENT OF A LARGE GROUP OF YOUNG PATIENTS WITH PD (N=150) OPEN LABEL STUDY; 20 GRAFTED WITH 3 YEAR FOLLOW UP and IMMUNOSUPPRESSION; 20 FOLLOWED WITH PET; 11O FOLLOWED CLINICALLY; ALL MOTOR ASSESSMENTS RATED BLINDLY 2010 OPTIMISED THE DELIVERY OF FETAL TISSUE INTO THE BRAIN 2014 STEPPING STONE TO STEM CELL TRANSPLANT TRIALS
9 TREATING PARKINSON S AND HUNTINGTON S DISEASE WITH CELL THERAPIES- WHY BOTHER? PARKINSON S DISEASE WHAT CAN WE SAY? Fetal VM transplants can work as well as best dopamine therapies; This therapeutic effect can last for >10 years; Currently very variable clinical response; Grafts can acquire a pathology but this is not a critical factor in the short term; This is not a CURE but may have a major impact on changing the natural history of treated PD
10 Huntington s Disease- An introduction Autosomal dominant driven by mutant huntingtin Starts between ages of Progresses over about 20 years from onset Expanded CAG repeat Mutant huntingtin Interferes with transcription STRATEGIES TRIED AMONGST OTHERS: Environmental enrichment Creatine supplementation Caspase inhibitors (minocyline) Regulators of proteosome Histone deacetylase inhibitors Activators of autophagy (rapamycin) sirna therapy Recent interest in NMDA-R mediated htt processing Aggregation of mutant protein/ Formation of inclusions Removed by UPS/autophagy Cellular dysfunction Altering glutamate signalling Causing excitotoxicity Cell Death
11 TREATING HUNTINGTON S DISEASE WITH CELL THERAPIES: WHY BOTHER? HUNTINGTON S DISEASE REASONS FOR: Relatively common; Incurable; Most people die of HD; Well defined early striatal pathology; Experimental studies show you can repair the excitotoxically lesioned striatum with fetal striatal grafts; Some grafted patients have done well; No effective therapy for HD unlike PD REASONS AGAINST: Pathology involves many nonstriatal sites from disease onset; Transplant studies in Tg mice have failed; Trials show it does not work for the majority of cases; Grafts can acquire HD pathology! Better approach is to target the pathogenic pathway involving mutant gene and its product
12 Huntington s disease: TRANSPLANT APPROACH Take patient with a neurodegenerative disorder such as HUNTINGTON S DISEASE Identify key pathology i.e. loss of strital projection neurons Transplant in striatal cells CURE Name Number of patients Improvement Post-mortem data Kopyov et al Yes short term Yes 2, poor graft integration 6 years post implantation with mass effect in 1 case Bachoud-Levi et al 2000 and Yes in 3/5 but now getting worse Rosser et al (5) No No Hauser et al No Yes- 1, with good graft survival but no clinical improvement and another with poor integration Tai et al 2 Yes 1 long term No No
13 Name Number of patients Improvement Post-mortem data Kopyov et al Yes short term Yes 2, poor graft integration 6 years post implantation with mass effect in 1 case Bachoud-Levi et al 2000 and Yes in 3/5 but now getting worse Rosser et al (5) No No Hauser et al No Yes- 1, with good graft survival but no clinical improvement and another with poor integration Tai et al 2 Yes 1 long term No No
14 Name Number of patients Improvement Post-mortem data Kopyov et al Yes short term Yes 2, poor graft integration 6 years post implantation with mass effect in 1 case Bachoud-Levi et al 2000 and Yes in 3/5 but now getting worse Rosser et al (5) No No Hauser et al No Yes- 1, with good graft survival but no clinical improvement and another with poor integration Tai et al 2 Yes 1 long term No No
15 Clinical Transplant Trial-Cambridge UK..and in Transplant group PET measurement of disease progression in HD 1.9 Mean reduction 5%/yr (range ~ ) 1.7 Total UHDRS Scores (higher =worse) 1.5 Raclopride BP Rstriat Lstriat No significant benefit clinically or on imaging Baseline T1 +1 T1 +2 T2 +1 Time
16 Name Number of patients Improvement Post-mortem data Kopyov et al Yes short term Yes 2, poor graft integration 6 years post implantation with mass effect in 1 case Bachoud-Levi et al 2000 and Yes in 3/5 but now getting worse Rosser et al (5) No No Hauser et al No Yes- 1, with good graft survival but no clinical improvement and another with poor integration Tai et al 2 Yes 1 long term No No
17 BUT a patient grafted at KCL Transplantation Subject 1 Subject 2 Controls Time (months) Total UHDRS Score Kings 1 Vs Controls Months Kings 1 Controls months Baseline post Tx DB Male CAG-repeat length 43 HD manifested clinically at age 46 when he developed chorea, aggression and depression. Grafted at KCH, London Last follow up 13 years post transplantation Reuter et al JNNP 2009
18 TREATING PARKINSON S AND HUNTINGTON S DISEASE WITH CELL THERAPIES- WHY BOTHER? PARKINSON S DISEASE WHAT CAN WE SAY? Fetal VM transplants can work as well as best dopamine therapies; This therapeutic effect can last for >10 years; Currently very variable clinical response; Grafts can acquire a pathology but this is not a critical factor in the short term; This is not a CURE but may have a major impact on changing the natural history of treated PD HUNTINGTON S DISEASE WHAT CAN WE SAY? Fetal striatal transplants can work in the short term; Fetal striatal grafts may ultimately be lost because of pathology of HD affecting the transplant; This will never be a CURE and is unlikely to have a major impact on changing the natural history of HD given the widespread pathology and problem in HD
19 THE TEAM involved over the years includes....main players in work mentioned today.. Tom Foltynie Tim Harrower Caroline Williams Gray Jonathan Evans Sarah Mason Aileen Ho Natalie Valle Guzman Main Collaborations : Trevor Robbins; Maria Grazia Spillantini; Adrian Owen; Carol Brayne; James Rowe; Stephen Sawcer; Alastair Compston; John Sinclair ; Harvey McMahon; Anna Philpott; Barbara Sahakian; Jenny Morton; David Rubinzstein (Cambridge); David Burn, Patrick Chinnery, David Brooks, Paola Piccini and UK- NEST network; Malin Parmar, Anders Bjorklund, Ernest Arenas, Elena Cattaneo (EU) Francesca Cicchetti (Canada) Our work has been supported by: MRC; PDS; Cure PD; Patrick Bertoud Trust; Rosetrees Trust; Raymond and Beverley Sackler Trust; NIHR-BRC/BRU ; Wellcome Trust; CHDI; Evelyn Trust and SCI.
Neuroscience 410 Huntington Disease - Clinical. March 18, 2008
Neuroscience 410 March 20, 2007 W. R. Wayne Martin, MD, FRCPC Division of Neurology University of Alberta inherited neurodegenerative disorder autosomal dominant 100% penetrance age of onset: 35-45 yr
More informationThe long-term safety and efficacy of bilateral transplantation of human fetal striatal tissue in patients with mild to moderate Huntington s disease
JNNP Online First, published on January 23, 2013 as 10.1136/jnnp-2012-302441 RESEARCH PAPER The long-term safety and efficacy of bilateral transplantation of human fetal striatal tissue in patients with
More informationEast of England Neurology Training Fellowships 2016
East of England Neurology Training Fellowships 2016 Neurology training in the East of England deanery is the only neurology training scheme in the UK focused on training in academic neurology. All trainees
More informationStrategies for Neurorestoration: Growth Factors
Strategies for Neurorestoration: Growth Factors Elena Posse de Chaves, PhD 928-MSB Phone: 492-5966 Email: elena.chaves@ualberta.ca Treatment of Neurodegenerative Diseases Most neurodegenerative diseases
More informationThe motor regulator. 1) Basal ganglia/nucleus
The motor regulator 1) Basal ganglia/nucleus Neural structures involved in the control of movement Basal Ganglia - Components of the basal ganglia - Function of the basal ganglia - Connection and circuits
More informationBasal Ganglia. Steven McLoon Department of Neuroscience University of Minnesota
Basal Ganglia Steven McLoon Department of Neuroscience University of Minnesota 1 Course News Graduate School Discussion Wednesday, Nov 1, 11:00am MoosT 2-690 with Paul Mermelstein (invite your friends)
More informationUNDERSTANDING PARKINSON S DISEASE
UNDERSTANDING PARKINSON S DISEASE WHAT IS PARKINSON S DISEASE? A progressive disease of the nervous system marked by tremor, muscular rigidity, and slow, imprecise movement, chiefly affecting middleaged
More informationA. General features of the basal ganglia, one of our 3 major motor control centers:
Reading: Waxman pp. 141-146 are not very helpful! Computer Resources: HyperBrain, Chapter 12 Dental Neuroanatomy Suzanne S. Stensaas, Ph.D. April 22, 2010 THE BASAL GANGLIA Objectives: 1. What are the
More informationCell transplantation in Parkinson s disease
Cell transplantation in Parkinson s disease Findings by SBU Alert Published September 18, 2001 Revised November 7, 2003 Version 2 Technology and target group: In Parkinsons disease, the brain cells that
More informationPathogenesis of Degenerative Diseases and Dementias. D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria)
Pathogenesis of Degenerative Diseases and Dementias D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria) Dementias Defined: as the development of memory impairment and other cognitive deficits
More informationLet s Look at Parkinson s (PD) Sheena Morgan Parkinson s Disease Nurse Specialist Isle of Wight NHS Trust November 2016
Let s Look at Parkinson s (PD) Sheena Morgan Parkinson s Disease Nurse Specialist Isle of Wight NHS Trust November 2016 What is Parkinson s? Parkinson's is a progressive neurological condition. People
More informationLecture XIII. Brain Diseases I - Parkinsonism! Brain Diseases I!
Lecture XIII. Brain Diseases I - Parkinsonism! Bio 3411! Wednesday!! Lecture XIII. Brain Diseases - I.! 1! Brain Diseases I! NEUROSCIENCE 5 th ed! Page!!Figure!!Feature! 408 18.9 A!!Substantia Nigra in
More informationA. General features of the basal ganglia, one of our 3 major motor control centers:
Reading: Waxman pp. 141-146 are not very helpful! Computer Resources: HyperBrain, Chapter 12 Dental Neuroanatomy Suzanne S. Stensaas, Ph.D. March 1, 2012 THE BASAL GANGLIA Objectives: 1. What are the main
More informationCheyenne 11/28 Neurological Disorders II. Transmissible Spongiform Encephalopathy
Cheyenne 11/28 Neurological Disorders II Transmissible Spongiform Encephalopathy -E.g Bovine4 Spongiform Encephalopathy (BSE= mad cow disease), Creutzfeldt-Jakob disease, scrapie (animal only) -Sporadic:
More informationHuntington s Disease COGS 172
Huntington s Disease COGS 172 Overview Part I: What is HD? - Clinical description and features - Genetic basis and neuropathology - Cell biology, mouse models and therapeutics Part II: HD as a model in
More informationMaking Things Happen 2: Motor Disorders
Making Things Happen 2: Motor Disorders How Your Brain Works Prof. Jan Schnupp wschnupp@cityu.edu.hk HowYourBrainWorks.net On the Menu in This Lecture In the previous lecture we saw how motor cortex and
More informationMETHOD FOR PREDICTING THE EARLY ONSET AND SEVERITY OF LEVODOPA INDUCED DYSKINESIA (LID) IN SUBJECTS DIAGNOSED OF PARKINSON S DISEASE
METHOD FOR PREDICTING THE EARLY ONSET AND SEVERITY OF LEVODOPA INDUCED DYSKINESIA (LID) IN SUBJECTS DIAGNOSED OF PARKINSON S DISEASE Madrid, 14 de noviembre de 2017 1. THE TEAM AND THE INSTITUTIONS BEHIND
More informationHow to Effectively Manage the Motor Symptoms of HD
How to Effectively Manage the Motor Symptoms of HD Yvette Bordelon, MD, PhD Associate Clinical Professor of Neurology David Geffen School of Medicine at UCLA The information provided by speakers in workshops,
More informationMovement Disorders. Psychology 372 Physiological Psychology. Background. Myasthenia Gravis. Many Types
Background Movement Disorders Psychology 372 Physiological Psychology Steven E. Meier, Ph.D. Listen to the audio lecture while viewing these slides Early Studies Found some patients with progressive weakness
More informationFirst described by James Parkinson in his classic 1817 monograph, "An Essay on the Shaking Palsy"
Parkinson's Disease First described by James Parkinson in his classic 1817 monograph, "An Essay on the Shaking Palsy" Parkinson s disease (PD) is a neurological disorder characterized by a progressive
More informationParkinson s Disease Foundation. PD ExpertBriefing: What s in the PD Pipeline? Gene and Cell Therapies
Parkinson s Disease Foundation PD ExpertBriefing: What s in the PD Pipeline? Gene and Cell Therapies Led By: Roger Barker, M.B.B.S, M.R.C.P, Ph.D., Professor of Clinical Neuroscience and Honorary Consultant,
More informationMETHOD FOR PREDICTING THE EARLY ONSET AND SEVERITY OF LEVODOPA INDUCED DYSKINESIA (LID) IN SUBJECTS DIAGNOSED OF PARKINSON S DISEASE
METHOD FOR PREDICTING THE EARLY ONSET AND SEVERITY OF LEVODOPA INDUCED DYSKINESIA (LID) IN SUBJECTS DIAGNOSED OF PARKINSON S DISEASE Con el respaldo de ACCIÓ Madrid, 14 de noviembre de 2017 1. THE TEAM
More informationNeurodegenerative Disease. April 12, Cunningham. Department of Neurosciences
Neurodegenerative Disease April 12, 2017 Cunningham Department of Neurosciences NEURODEGENERATIVE DISEASE Any of a group of hereditary and sporadic conditions characterized by progressive dysfunction,
More informationFENS Neuroethics Seminar. The William Safire Seminar on Neuroethics FENS 2012 Barcelona July 15, 2012
FENS Neuroethics Seminar The William Safire Seminar on Neuroethics FENS 2012 Barcelona July 15, 2012 Invading the Brain: What are the Ethical Issues on Invasive Treatments for Brain Disorders? DBS for
More informationTREATMENT OF PARKINSON S DISEASE BY CELL TRANSPLANTATION
TREATMENT OF PARKINSON S DISEASE BY CELL TRANSPLANTATION Pierre Cesaro, Marc Peschanski, Jean-Paul N Guyen Department of Medical Neurosciences and INSERM U 421, Henri Mondor Hospital, Créteil, France Reprint
More informationDrugs used in Huntington s. disease
Drugs used in Huntington s HD can intensify in next generation disease The number of CAG repeats The age in which the symptom of HD to appear healthy person ill person dead person Drugs used in Huntington
More informationObjectives. What is a stem cell? 2/5/2014. Stem Cells for Incurable Diseases? Hope for New Treatments for Parkinson's Disease
Stem Cells for Incurable Diseases? Hope for New Treatments for Parkinson's Disease Vicki Wheelock MD Health Sciences Clinical Professor Department of Neurology February 8, 2014 Objectives Stem cells 101
More informationPrecise evaluation of motor and non-motor dysfunction in Parkinson s disease using the KINARM
Precise evaluation of motor and non-motor dysfunction in Parkinson s disease using the KINARM Project lead: Dr. Ron Levy Pauline Gaprielian, Dr. Stephen H. Scott, Dr. Giovanna Pari Queen s University,
More informationLIHR La ricerca sulle malattie rare e le prospettive di cura per la malattia di Huntington. Neuroscience, the Future is Bright
LIHR La ricerca sulle malattie rare e le prospettive di cura per la malattia di Huntington Neuroscience, the Future is Bright Mauro Patroncini, MD Pipeline Product Strategy Leader Luisa De Stefano Head
More informationCell Therapy in Parkinson s Disease
NeuroRx : The Journal of the American Society for Experimental NeuroTherapeutics Cell Therapy in Parkinson s Disease Olle Lindvall and Anders Björklund Wallenberg Neuroscience Center and Lund Strategic
More informationNumber: Policy. Last Review 07/14/2016 Effective: 05/14/2002 Next Review: 07/13/2017. *Please see amendment for Pennsylvania Medicaid at the
1 of 24 Number: 0614 Policy *Please see amendment for Pennsylvania Medicaid at the end of this CPB. Aetna considers putaminal magnetic resonance spectroscopy measurements of myo inositol and N acetylaspartate
More informationWhich Patients with Parkinson s Disease Participate in Clinical Trials? One Centre s Experiences with a New Cell Based Therapy Trial (TRANSEURO)
Journal of Parkinson s Disease 4 (2014) 671 676 DOI 10.3233/JPD-140432 IOS Press Research Report 671 Which Patients with Parkinson s Disease Participate in Clinical Trials? One Centre s Experiences with
More informationHuntington s Disease. An Update on Latest Research. HD Center of Excellence
Huntington s Disease An Update on Latest Research HD Treatment gcurrent treatments are symptomatic. gseveral compounds have delayed onset and slowed progression in mouse models. gquestion remains to translate
More informationDamage on one side.. (Notes) Just remember: Unilateral damage to basal ganglia causes contralateral symptoms.
Lecture 20 - Basal Ganglia Basal Ganglia (Nolte 5 th Ed pp 464) Damage to the basal ganglia produces involuntary movements. Although the basal ganglia do not influence LMN directly (to cause this involuntary
More informationMaking Every Little Bit Count: Parkinson s Disease. SHP Neurobiology of Development and Disease
Making Every Little Bit Count: Parkinson s Disease SHP Neurobiology of Development and Disease Parkinson s Disease Initially described symptomatically by Dr. James Parkinson in 1817 in An Essay on the
More informationUSING PRECISION MEDICINE TO HELP PATIENTS WITH PARKINSON S DISEASE. The Michael J. Fox Foundation for Parkinson s Research
USING PRECISION MEDICINE TO HELP PATIENTS WITH PARKINSON S DISEASE The Michael J. Fox Foundation for Parkinson s Research MJFF IS THE WORLD S LARGEST NONPROFIT FUNDER OF PD RESEARCH Our Mission We are
More informationPart 1 Parkinson s Disease. COGS 172: Brain Disorders and Cogni5on
Part 1 Parkinson s Disease COGS 172: Brain Disorders and Cogni5on Background: Neuroanatomy of the motor system Note: Given short time to the final the details of the anatomy will not be in the exam, but
More informationCDNF: Finnish academia-industry collaboration for unique clinical study in Parkinson s disease
CDNF: Finnish academia-industry collaboration for unique clinical study in Parkinson s disease Brain Diseases Symposium, Helsinki 14 Oct 2016 Pekka Simula, CEO, Herantis Pharma Plc 1 Disclaimer This presentation
More informationThe Parkinson s You Can t See
The Parkinson s You Can t See We principally see the motor phenomena of Parkinson's disease, but is there an early stage without visible features? Might this provide a window for disease-modifying therapy?
More informationDISORDERS OF THE MOTOR SYSTEM. Jeanette J. Norden, Ph.D. Professor Emerita Vanderbilt University School of Medicine
DISORDERS OF THE MOTOR SYSTEM Jeanette J. Norden, Ph.D. Professor Emerita Vanderbilt University School of Medicine THE MOTOR SYSTEM To understand disorders of the motor system, we need to review how a
More informationBasal ganglia Sujata Sofat, class of 2009
Basal ganglia Sujata Sofat, class of 2009 Basal ganglia Objectives Describe the function of the Basal Ganglia in movement Define the BG components and their locations Describe the motor loop of the BG
More informationIII./3.1. Movement disorders with akinetic rigid symptoms
III./3.1. Movement disorders with akinetic rigid symptoms III./3.1.1. Parkinson s disease Parkinson s disease (PD) is the second most common neurodegenerative disorder worldwide after Alzheimer s disease.
More informationGenetic mouse models of Huntington s and Parkinson s diseases: illuminating but imperfect
Review TRENDS in Neurosciences Vol.27 No.11 November 2004 Genetic mouse models of Huntington s and Parkinson s diseases: illuminating but imperfect Michael S. Levine 1, Carlos Cepeda 1, Miriam A. Hickey
More informationPREDICT-HD. PREDICT-HD: Paving the Way Toward Clinical Trials. Dr. Jane Paulsen Principal Investigator PREDICT-HD
: Paving the Way Toward Clinical Trials Dr. Jane Paulsen Principal Investigator Professor of Neurology, Psychiatry, Psychology and Neuroscience University of Iowa Carver College of Medicine Disclosures
More informationKinematic Modeling in Parkinson s Disease
Kinematic Modeling in Parkinson s Disease Alexander Hui Department of Bioengineering University of California, San Diego La Jolla, CA 92093 alexhui@ucsd.edu Abstract Parkinson s disease is a slowly progressing
More informationOverview. Overview. Parkinson s disease. Secondary Parkinsonism. Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits
Overview Overview Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits The differential diagnosis of Parkinson s disease Primary vs. Secondary Parkinsonism Proteinopathies:
More informationNew Approach to Parkinson s Disease: Synuclein Immunotherapy
RB2014 Conference August 22, 2014 New Approach to Parkinson s Disease: Synuclein Immunotherapy Dale Schenk, PhD President and CEO Prothena Corporation plc Primary Motor and Non-Motor Symptoms of Parkinson
More informationBORDEAUX MDS WINTER SCHOOL FOR YOUNG
BORDEAUX MDS WINTER SCHOOL FOR YOUNG NEUROLOGISTS HOW TO EVALUATE MOTOR COMPLICATIONS IN PARKINSON'S DISEASE T. Henriksen Tove Henriksen, MD MDS Clinic University Hospital of Bispebjerg, Copenhagen MOTOR
More informationNews in brief. March, New post-doc att TNU wants to boost neuroscience in Pakistan
BAGADILICO News March, 2011 New post-doc att TNU wants to boost neuroscience in Pakistan Ummar Sajjad, born and raised in Lahore, Pakistan, has recently started his postdoctoral fellowship at the Translational
More informationParkinson s Disease. Prevalence. Mark S. Baron, M.D. Cardinal Features. Clinical Characteristics. Not Just a Movement Disorder
Prevalence Parkinson s Disease Mark S. Baron, M.D. Associate Professor of Neurology Movement Disorders Section VCU School of Medicine Common disorder Approaching 1% by 65 yrs of age, 2% by 80 yrs of age
More informationCase Study 2: Neurological Degenerative Disease FDA Regulatory and Clinical Background
Case Study 2: Neurological Degenerative Disease FDA Regulatory and Clinical Background Heather Benz, Ph.D. FDA Center for Devices and Radiological Health Neurological Degenerative Diseases Neurodegenerative
More informationTwo multidisciplinary teams of investigators have
Dopamine Cell Implantation in Parkinson s Disease: Long-Term Clinical and F-FDOPA PET Outcomes Yilong Ma 1,2, Chengke Tang 1, Thomas Chaly 1,2, Paul Greene 3, Robert Breeze 4, Stanley Fahn 3, Curt Freed
More informationTreatment of Parkinson s Disease: Present and Future
Treatment of Parkinson s Disease: Present and Future Karen Blindauer, MD Professor of Neurology Director of Movement Disorders Program Medical College of Wisconsin Neuropathology: Loss of Dopamine- Producing
More informationSurgical Management of Parkinson s Disease
Surgical Management of Parkinson s Disease Shyamal H. Mehta MD, PhD Assistant Professor of Neurology, Movement Disorders Division Mayo Clinic College of Medicine Mayo Clinic, Arizona 2016 MFMER slide-1
More informationSubthalamic Nucleus Deep Brain Stimulation (STN-DBS)
Subthalamic Nucleus Deep Brain Stimulation (STN-DBS) A Neurosurgical Treatment for Parkinson s Disease Parkinson s Disease Parkinson s disease is a common neurodegenerative disorder that affects about
More informationKelly Mills, MD, MHS Johns Hopkins Parkinson s Disease and Movement Disorders Center
Kelly Mills, MD, MHS Johns Hopkins Parkinson s Disease and Movement Disorders Center Disclosures Research support from St. Jude / Abbott Funding National Institutes of Health / NINDS Parkinson Foundation
More informationNovel Targets of disease modifying therapy for Parkinson disease. David G. Standaert, MD, PhD John N. Whitaker Professor and Chair of Neurology
Novel Targets of disease modifying therapy for Parkinson disease David G. Standaert, MD, PhD John N. Whitaker Professor and Chair of Neurology Disclosures Dr. Standaert has served as a paid consultant
More informationInvestigating molecular mechanisms of progression of Parkinson s Disease in human brain
Investigating molecular mechanisms of progression of Parkinson s Disease in human brain Murray ; C.E., Pressey ; S.N., Heywood 2 ; W.E., Hargreaves 3 ; I.P., Neergheen 3 ; V., Wauters ; S., Palkovits 4
More informationParkinson disease: Parkinson Disease
Surgical Surgical treatment treatment for for Parkinson disease: Parkinson Disease the Present and the Future the Present and the Future Olga Klepitskaya, MD Associate Professor of Neurology Co-Director,
More informationChapter 20. Media Directory. Amyotrophic Lateral Sclerosis. Alzheimer s Disease. Huntington s Chorea. Multiple Sclerosis
Chapter 20 Drugs for Degenerative Diseases of the Nervous System Slide 18 Media Directory Levadopa Animation Upper Saddle River, New Jersey 07458 All rights reserved. Alzheimer s Disease Amyotrophic Lateral
More informationPD ExpertBriefing: The Effects of Exercise on PD
PD ExpertBriefing: The Effects of Exercise on PD Led By: Margaret Schenkman, P.T., Ph.D., F.A.P.T.A. Associate Dean for Physical Therapy Education, and Director, Physical Therapy Program, University of
More informationCell Transplant Therapy for Parkinson s Disease: Triumphs and Challenges in Clinical Research.
Clinical Reviews 23 Cell Transplant Therapy for Parkinson s Disease: Triumphs and Challenges in Clinical Research Authors: Lindsay Dolomount BSc 1 1 Memorial University of Newfoundland, St John s, NL Author
More informationDementia Update. October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada
Dementia Update October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada Outline New concepts in Alzheimer disease Biomarkers and in vivo diagnosis Future trends
More informationCannabinoids and Dementia: A Review of Clinical and Preclinical Data
Cannabinoids and Dementia: A Review of Clinical and Preclinical Data Abstract: The endocannabinoid system has been shown to be associated with neurodegenerative diseases and dementia. We review the preclinical
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/32744 holds various files of this Leiden University dissertation Author: Heemskerk, Anne-Wil Title: Dysphagia in Huntington s disease Issue Date: 2015-04-15
More informationMay 9, Q Financial Results
May 9, 2017 Q1 2017 Financial Results Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Steve Kanes, M.D., Ph.D., Chief Medical Officer Kimi
More informationdoi: /brain/awq328 Brain 2011: 134;
doi:10.1093/brain/awq328 Brain 2011: 134; 641 652 641 BRAIN A JOURNAL OF NEUROLOGY REVIEW ARTICLE Neuronal degeneration in striatal transplants and Huntington s disease: potential mechanisms and clinical
More informationMOVEMENT OUTLINE. The Control of Movement: Muscles! Motor Reflexes Brain Mechanisms of Movement Mirror Neurons Disorders of Movement
MOVEMENT 2 Dr. Steinmetz 3 OUTLINE The Control of Movement: Muscles! Motor Reflexes Brain Mechanisms of Movement Mirror Neurons Disorders of Movement Parkinson s Disease Huntington s Disease 1 4 TYPES
More informationDopamine cell transplantation in Parkinson s disease: challenge and perspective
Published Online August 28, 2011 Dopamine cell transplantation in Parkinson s disease: challenge and perspective Yilong Ma *, Shichun Peng, Vijay Dhawan, and David Eidelberg Center for Neurosciences, The
More informationThe Shaking Palsy of 1817
The Shaking Palsy of 1817 A Treatment Update on Parkinson s Disease Dr Eitzaz Sadiq Neurologist CH Baragwanath Acadamic Hospital Parkinson s Disease O Premature death of dopaminergic neurons O Symptoms
More informationModeling Parkinson s disease: systems to test gene-environment interactions
Modeling Parkinson s disease: systems to test gene-environment interactions Jason Cannon, Ph.D. Pittsburgh Institute of Neurodegenerative Diseases University of Pittsburgh Outline Parkinson s disease (PD)
More informationMechanisms of L-DOPA-induced dyskinesia in Parkinson s Disease M. Angela Cenci
Mechanisms of L-DOPA-induced Dyskinesia in Parkinson s Disease 1 Prof., MD, PhD Professor of Experimental Medical Research Basal Ganglia Pathophysiology Unit Lund University, Lund (Sweden) Parkinson s
More informationVL VA BASAL GANGLIA. FUNCTIONAl COMPONENTS. Function Component Deficits Start/initiation Basal Ganglia Spontan movements
BASAL GANGLIA Chris Cohan, Ph.D. Dept. of Pathology/Anat Sci University at Buffalo I) Overview How do Basal Ganglia affect movement Basal ganglia enhance cortical motor activity and facilitate movement.
More informationParkinson s Disease. Sirilak yimcharoen
Parkinson s Disease Sirilak yimcharoen EPIDEMIOLOGY ~1% of people over 55 years Age range 35 85 years peak age of onset is in the early 60s ~5% of cases characterized by an earlier age of onset (typically
More informationRecent advances in stem cell technologies have. Long-term Clinical Outcome of Fetal Cell Transplantation for Parkinson Disease Two Case Reports
Research Case Report/Case Series Long-term Clinical Outcome of Fetal Cell Transplantation for Parkinson Disease Two Case Reports Zinovia Kefalopoulou, MD, PhD; Marios Politis, MD, PhD; Paola Piccini, MD,
More informationDr Barry Snow. Neurologist Auckland District Health Board
Dr Barry Snow Neurologist Auckland District Health Board Dystonia and Parkinson s disease Barry Snow Gowers 1888: Tetanoid chorea Dystonia a movement disorder characterized by sustained or intermittent
More informationPD ExpertBriefings: Parkinson s Medications: Today and Tomorrow Led By: Cynthia L. Comella, M.D., F.A.A.N.
PD ExpertBriefings: Parkinson s Medications: Today and Tomorrow Led By: Cynthia L. Comella, M.D., F.A.A.N. To hear the session live on: Tuesday, April 17, 2012 at 1:00 PM ET. DIAL: 1 (888) 272-8710 and
More informationParkinson s Disease. Gillian Sare
Parkinson s Disease Gillian Sare Outline Reminder about PD Parkinson s disease in the inpatient Surgical patients with PD Patients who cannot swallow End of life care Parkinson s disease PD is the second
More informationDRUG TREATMENT OF PARKINSON S DISEASE. Mr. D.Raju, M.pharm, Lecturer
DRUG TREATMENT OF PARKINSON S DISEASE Mr. D.Raju, M.pharm, Lecturer PARKINSON S DISEASE (parkinsonism) is a neurodegenerative disorder which affects t h e b a s a l g a n g l i a - and is associated with
More informationIdentification number: TÁMOP /1/A
Manifestation of Novel Social Challenges of the European Union in the Teaching Material of Medical Biotechnology Master s Programmes at the University of Pécs and at the University of Debrecen Identification
More informationPARKINSON S MEDICATION
PARKINSON S MEDICATION History 1940 50 s Neurosurgeons operated on basal ganglia. Improved symptoms. 12% mortality 1960 s: Researchers identified low levels of dopamine caused Parkinson s leading to development
More informationCOGNITIVE SCIENCE 107A. Motor Systems: Basal Ganglia. Jaime A. Pineda, Ph.D.
COGNITIVE SCIENCE 107A Motor Systems: Basal Ganglia Jaime A. Pineda, Ph.D. Two major descending s Pyramidal vs. extrapyramidal Motor cortex Pyramidal system Pathway for voluntary movement Most fibers originate
More informationGenetic Parkinson s studying the few to treat the many
Edinburgh Talk 01.12.12 Genetic Parkinson s studying the few to treat the many Miratul Muqit, Wellcome Trust Intermediate Fellow, Honorary Consultant Neurologist, MRC Protein Phosphorylation Unit, University
More informationTranscranial sonography in movement disorders
Transcranial sonography in movement disorders Uwe Walter 1st Residential Training of the European Society of Neurosonology and Cerebral Hemodynamics September 7-12, 2008 Bertinoro, Italy Department of
More informationParkinson s Disease Webcast January 31, 2008 Jill Ostrem, M.D. What is Parkinson s Disease?
Parkinson s Disease Webcast January 31, 2008 Jill Ostrem, M.D. Please remember the opinions expressed on Patient Power are not necessarily the views of UCSF Medical Center, its medical staff or Patient
More informationlevodopa-induced dyskinesia
Journal of Neurology, Neurosurgery, and Psychiatry, 1978, 41, 702-706 Sodium valproate in the treatment of levodopa-induced dyskinesia P. A. PRICE, J. D. PARKES, AND C. D. MARSDEN From the University Department
More information05-Nov-15. Impact of Parkinson s Disease in Australia. The Nature of Parkinson s disease 21st Century
Peter Silburn Professor Clinical Neuroscience University of Queensland Queensland Brain Institute Neurosciences Queensland Impact of in Australia Second most common neurodegenerative disorder Up to 64,000
More informationWelcome and Introductions
Parkinson s Disease Spotlight on Treatment Advances Tuesday, January 26, 2016 Welcome and Introductions Stephanie Paul Vice President Development and Marketing American Parkinson Disease Association 1
More informationOverview of neurological changes in Alzheimer s disease. Eric Karran
Overview of neurological changes in Alzheimer s disease Eric Karran Alzheimer s disease Alois Alzheimer 1864-1915 Auguste D. 1850-1906 Case presented November 26 th 1906 Guildford Talk.ppt 20 th March,
More informationPalladotomy and Pallidal Deep Brain Stimulation
Palladotomy and Pallidal Deep Brain Stimulation Parkinson s disease Parkinson s Disease is a common neurodegenerative disorder that affects about 1:100 individuals over the age of 60. In a small percentage
More informationParkinson's Disease KP Update
Parkinson's Disease KP Update Andrew Imbus, PA-C Neurology, Movement Disorders Kaiser Permanente, Los Angeles Medical Center No disclosures "I often say now I don't have any choice whether or not I have
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name Parkinson disease 8, automsomal dominant OMIM number for disease 607060 Disease
More informationProgress. The research magazine of Parkinson s UK. Animal models of Parkinson s: why do we need them? Issue 9: summer 2011
The research magazine of Parkinson s UK Issue 9: summer 2011 Animal models of Parkinson s: why do we need them? Contents Welcome 3 From Dr Kieran Breen, Director of Research and Development Animal models
More informationWelcome and Introductions
Parkinson s Disease Spotlight on Addressing Motor and Non-Motor Symptoms The Changing Landscape Wednesday, March 8, 2017 Welcome and Introductions Stephanie Paul Vice President Development and Marketing
More informationNEURAL CONTROL OF MOVEMENT: ENGINEERING THE RHYTHMS OF THE BRAIN
NEURAL CONTROL OF MOVEMENT: ENGINEERING THE RHYTHMS OF THE BRAIN Madeleine Lowery School of Electrical and Electronic Engineering Centre for Biomedical Engineering University College Dublin Parkinson s
More informationINCREASING FUNCTIONALITY AND THE QUALITY OF LIFE THROUGH MEDICAL REHABILITATION IN PATIENTS WITH PARKINSON S DISEASE
INCREASING FUNCTIONALITY AND THE QUALITY OF LIFE THROUGH MEDICAL REHABILITATION IN PATIENTS WITH PARKINSON S DISEASE Moldovan Andreea Alexandra², Dogaru Gabriela 1,2 ¹University of Medecine and Pharmacy
More informationRecent Advances in the cause and treatment of Parkinson disease. Anthony Schapira Head of Dept. Clinical Neurosciences UCL Institute of Neurology UCL
Recent Advances in the cause and treatment of Parkinson disease Anthony Schapira Head of Dept. Clinical Neurosciences UCL Institute of Neurology UCL SOME BACKGROUND incidence rate (per 100.000 person years)
More informationA Four Point Plan for Enhanced Support for Parkinson s Disease In B.C.
A Four Point Plan for Enhanced Support for Parkinson s Disease In B.C. February 14, 2017 Executive Summary More than 13,300 British Columbians live with Parkinson s Disease (PD) and our aging population
More informationAdverse outcome pathways to bridge the gap between epidemiology and experimental neurotoxicology
Adverse outcome pathways to bridge the gap between epidemiology and experimental neurotoxicology Marcel Leist In Vitro Toxicology and Biomedicine Doerenkamp-Zbinden Chair, University of Konstanz, Germany
More informationdipraglurant in Parkinson s disease
dipraglurant in Parkinson s disease broad potential for a novel mechanism January 2012 1 disclaimer These materials do not constitute or form part, or all, of any offer or invitation to sell or issue,
More information